Alnylam Pharmaceuticals (ALNY) Receivables (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Receivables data on file, last reported at $912.7 million in Q2 2026.

• Quarterly Receivables rose 60.95% year-over-year to $912.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $912.7 million (up 60.95% YoY) and the FY2025 annual result came in at $777.6 million, up 91.85% from the prior year.
• Receivables climbed to $912.7 million in Q2 2026, from $884.0 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $964.8 million in Q3 2025 to a low of $142.3 million in Q2 2022.
• A 5-year average of $429.4 million and a median of $326.6 million in 2023 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables tumbled 78.0% — and 2025, when it soared 172.65%.
• Tracing ALNY's Receivables over 5 years: stood at $238.0 million in 2022, then surged by 37.75% to $327.8 million in 2023, then grew by 23.65% to $405.3 million in 2024, then soared by 91.85% to $777.6 million in 2025, then rose by 17.38% to $912.7 million in 2026.
• The last three Receivables figures came in at $912.7 million (Q2 2026), $884.0 million (Q1 2026), and $777.6 million (Q4 2025), per Business Quant data.